AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12772004 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine
Number of subjects: 221
Study 11262983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (1.5 mg/kg/dose)
Number of subjects: 89
Study 11262983 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (10.0 mg/kg/dose)
Number of subjects: 89
Study 11262983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-paracetamol combination (10.0 mg/kg/dose)
Number of subjects: 89
Study 9091331 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a plus OC
Number of subjects: 30
Study 9091331 — intervention group
Group type: COMPARATOR
Intervention: OC alone
Number of subjects: 30
Study 8392581 — intervention group
Group type: EXPERIMENTAL
Intervention: High power density (HPD) laser treatment (60 W, spot size 1-1.5 mm)
Number of subjects: 204
Study 8392581 — intervention group
Group type: COMPARATOR
Intervention: Low power density (LPD) laser treatment (20 W, spot size 1-1.5 mm)
Number of subjects: 204
Study 3549473 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg bd
Number of subjects: 67
Study 3549473 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 1 g qid
Number of subjects: 67
Study 3549473 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs continued during treatment
Number of subjects: 67
Study 3549473 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs stopped during treatment
Number of subjects: 67
Study 3549473 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 67
Study 3549473 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 month follow up
Number of subjects: 67
Study 31297799 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergent Thinking exercises without examples
Number of subjects: 120
Study 31297799 — intervention group
Group type: COMPARATOR
Intervention: Divergent Thinking exercises with examples
Number of subjects: 120
Study 31297799 — intervention group
Group type: COMPARATOR
Intervention: Neutral control exercises
Number of subjects: 120
Study 30587217 — intervention group
Group type: COMPARATOR
Intervention: Current standard treatment
Number of subjects: 340
Study 27966023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth
Number of subjects: 50
Study 27966023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24718082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (n = 38)
Number of subjects: 80
Study 24718082 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (n = 40)
Number of subjects: 80
Study 23972294 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mm Hg
Number of subjects: 171
Study 23972294 — intervention group
Group type: COMPARATOR
Intervention: 20 mm Hg
Number of subjects: 171
Study 19955694 — intervention group
Group type: EXPERIMENTAL
Intervention: Class Ia antiarrhythmic agents
Number of subjects: 419
Study 19955694 — intervention group
Group type: EXPERIMENTAL
Intervention: Class Ib antiarrhythmic agents
Number of subjects: 419
Study 19955694 — intervention group
Group type: EXPERIMENTAL
Intervention: Class Ic antiarrhythmic agents
Number of subjects: 419
Study 19955694 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III antiarrhythmic agents
Number of subjects: 419
Study 18398154 — intervention group
Group type: EXPERIMENTAL
Intervention: bexarotene 400 mg/m(2)/d with cisplatin/vinorelbine
Number of subjects: 623
Study 18398154 — intervention group
Group type: COMPARATOR
Intervention: cisplatin/vinorelbine alone
Number of subjects: 623
Study 17114152 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (100% of resting motor threshold, 30 pulses at 10 Hz for 5 min)
Number of subjects: 15
Study 17114152 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS (audio recording of actual TMS stimulus sounds)
Number of subjects: 15
Study 15125904 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (Singulair) 10 mg daily for two menstrual cycles
Number of subjects: 25
Study 15125904 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two menstrual cycles
Number of subjects: 25
Study 15125904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg tablets) as needed
Number of subjects: 25
Study 11515643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health care education (OHCE) for nursing home caregivers
Number of subjects: 22
Study 11515643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OHCE)
Number of subjects: 22
Study 9763500 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A-hepatitis B vaccine administered at 0, 1, and 6 months
Number of subjects: 160
Study 7816991 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 micrograms)
Number of subjects: 22
Study 7816991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3144686 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 195
Study 3144686 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (base)
Number of subjects: 195
Study 3144686 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (stearate)
Number of subjects: 195
Study 3144686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (previous study)
Number of subjects: 195
Study 3144686 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (overall)
Number of subjects: 195
Study 28631050 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion rate titrated to keep ANI monitoring values between 50–70 (Group ANI, n: 22)
Number of subjects: 44
Study 28631050 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion rate regulated according to hemodynamic parameters (Group control, n: 22)
Number of subjects: 44
Study 28475555 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine with 2 μg/ml fentanyl
Number of subjects: 215
Study 28475555 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine with 2 μg/ml neostigmine
Number of subjects: 215
Study 28475555 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine with 4 μg/ml neostigmine
Number of subjects: 215
Study 28475555 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine with 8 μg/ml neostigmine
Number of subjects: 215
Study 25602863 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention consisting of 3 mailings and 1 coaching call
Number of subjects: 498
Study 25602863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 498
Study 23664565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 50
Study 23664565 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 50
Study 23664565 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 21364505 — intervention group
Group type: COMPARATOR
Intervention: Propofol with saline (control group)
Number of subjects: 67
Study 21364505 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 2.5 ng mL(‐1) of remifentanil (low‐remifentanil group)
Number of subjects: 67
Study 21364505 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 5.0 ng mL(‐1) of remifentanil (high‐remifentanil group)
Number of subjects: 67
Study 18482661 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 10001
Study 18482661 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 10001
Study 16488434 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine continuous infusion for 120 hours
Number of subjects: 27
Study 16488434 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution continuous infusion for 120 hours
Number of subjects: 27
Study 16488434 — intervention group
Group type: COMPARATOR
Intervention: Standard axillary lymph node dissection
Number of subjects: 27
Study 14515673 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative educational intervention (EG)
Number of subjects: 2
Study 14515673 — intervention group
Group type: COMPARATOR
Intervention: Traditional educational intervention (CG)
Number of subjects: 2
Study 14515673 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups after interventions
Number of subjects: 2
Study 10881620 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-practice
Number of subjects: 2
Study 10881620 — intervention group
Group type: COMPARATOR
Intervention: Blocked-practice
Number of subjects: 2
Study 9120459 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoprecipitation of (125)I‐glutamic acid decarboxylase
Number of subjects: 18
Study 8409313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomous listening (DL) to induce stress
Number of subjects: 20
Study 8409313 — intervention group
Group type: COMPARATOR
Intervention: Non-DL control test
Number of subjects: 20
Study 3530032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline 7.5 mg
Number of subjects: 15
Study 3530032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28737261 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cognitive‐behavioural therapy for PGD (PG‐CBT)
Number of subjects: 51
Study 28737261 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 51
Study 27707827 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily for 2 years)
Number of subjects: 250
Study 27707827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched, for 2 years)
Number of subjects: 250
Study 27707827 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 250
Study 27707827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 24680148 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal endoscopic surgery
Number of subjects: 40
Study 24680148 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic approach (control)
Number of subjects: 40
Study 22856254 — intervention group
Group type: EXPERIMENTAL
Intervention: Wool underwear (treatment group)
Number of subjects: 48
Study 22856254 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 21189769 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv system
Number of subjects: 40
Study 21189769 — intervention group
Group type: COMPARATOR
Intervention: 10% sodium hypochlorite gel
Number of subjects: 40
Study 17140704 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontotemporal dementia patients
Number of subjects: 132
Study 17140704 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 132
Study 15955465 — intervention group
Group type: EXPERIMENTAL
Intervention: Step‐One‐Diet plus glucomannan in gelatine capsules
Number of subjects: 40
Study 15955465 — intervention group
Group type: COMPARATOR
Intervention: Step‐One‐Diet only (control)
Number of subjects: 40
Study 14610118 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ42 levels in patients with AD at baseline and those who developed AD during follow-up
Number of subjects: 530
Study 14610118 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ42 levels in the highest quartile
Number of subjects: 530
Study 14610118 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ42 levels in patients with AD who died during follow-up
Number of subjects: 530
Study 14610118 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ42 levels in patients with newly acquired AD
Number of subjects: 530
Study 14610118 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ40 levels
Number of subjects: 530
Study 10390735 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant coping
Number of subjects: 61
Study 10390735 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 61
Study 8558225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 179
Study 8558225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 1910798 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine (10 mg IV bolus injections)
Number of subjects: 60
Study 1910798 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (80 microgram IV bolus injections)
Number of subjects: 60
Study 1910798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 7034927 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400‐rad craniospinal RT plus 1200‐rad extended‐field RT
Number of subjects: 724
Study 7034927 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400‐rad craniospinal RT
Number of subjects: 724
Study 7034927 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400‐rad cranial RT plus i.t. MTX
Number of subjects: 724
Study 7034927 — intervention group
Group type: COMPARATOR
Intervention: i.t. MTX alone
Number of subjects: 724
Study 7034927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial RT plus i.t. MTX
Number of subjects: 724
Study 7034927 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 724
Study 31887309 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg + metformin 1700 mg daily + lifestyle
Number of subjects: 144
Study 31887309 — intervention group
Group type: COMPARATOR
Intervention: metformin 1700 mg daily + lifestyle
Number of subjects: 144
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality SSC implementation
Number of subjects: 3702
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming blankets
Number of subjects: 3702
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic administration postincision
Number of subjects: 3702
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic administration preincision
Number of subjects: 3702
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadministration of antibiotics
Number of subjects: 3702
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical infections
Number of subjects: 3702
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: SSC effect on surgical infections
Number of subjects: 3702
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics provided before incision
Number of subjects: 3702
Study 29112512 — intervention group
Group type: EXPERIMENTAL
Intervention: SSC implementation
Number of subjects: 3702
Study 29856288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine
Number of subjects: 0
Study 27800705 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV counseling and testing (HBHCT) by lay counselors
Number of subjects: 406
Study 27800705 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of pre-test and post-test counseling sessions
Number of subjects: 406
Study 23813190 — intervention group
Group type: EXPERIMENTAL
Intervention: Head camera visual analysis during naming events
Number of subjects: 0
Study 23813190 — intervention group
Group type: EXPERIMENTAL
Intervention: Learned object names
Number of subjects: 0
Study 22452536 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml reciprocating procedure device (RPD) mechanical syringe
Number of subjects: 10
Study 22452536 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ml vacuum syringe
Number of subjects: 10
Study 19890774 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (dosage not specified)
Number of subjects: 8506
Study 18260957 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg o.d.)
Number of subjects: 32
Study 18260957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg o.d.)
Number of subjects: 32
Study 18260957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Valsartan and Fluvastatin
Number of subjects: 32
Study 15821899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound therapy for 20 min daily for 6 weeks
Number of subjects: 30
Study 15821899 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound device (Control)
Number of subjects: 30
Study 15821899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound therapy
Number of subjects: 30
Study 11817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine coated CPB circuit
Number of subjects: 20
Study 11817528 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncoated CPB circuit)
Number of subjects: 20
Study 10862437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural pain management programme (10 half day sessions)
Number of subjects: 58
Study 10862437 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 58
Study 9121849 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 164
Study 1359139 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril treatment (mean daily dose 69.1 mg)
Number of subjects: 42
Study 1359139 — intervention group
Group type: COMPARATOR
Intervention: Continuous beta-blockade
Number of subjects: 42
Study 3913160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (tamoxifen, fluorouracil, vincristine, methotrexate, cyclophosphamide, mitoxantrone)
Number of subjects: 67
Study 3913160 — intervention group
Group type: COMPARATOR
Intervention: Perioperative radiotherapy
Number of subjects: 67
Study 31399931 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 IU of vitamin D3 per day
Number of subjects: 83
Study 31399931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 29131093 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 34
Study 29131093 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 34
Study 26920994 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ± 1 calendar days of antibiotics
Number of subjects: 112
Study 26920994 — intervention group
Group type: COMPARATOR
Intervention: Maximum of 10 calendar days of therapy
Number of subjects: 112
Study 24206578 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56(+) APL
Number of subjects: 239
Study 24206578 — intervention group
Group type: COMPARATOR
Intervention: CD56(-) APL
Number of subjects: 239
Study 22723577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure therapy (systolic <120 mmHg)
Number of subjects: 4687
Study 22723577 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure therapy (systolic <140 mmHg)
Number of subjects: 4687
Study 22723577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure therapy
Number of subjects: 4687
Study 20109119 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 245
Study 18485128 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 24
Study 18485128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 24
Study 18485128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 24
Study 18485128 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Omeprazole, Pantoprazole, Lansoprazole)
Number of subjects: 24
Study 16421033 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized written home-management plan
Number of subjects: 0
Study 16421033 — intervention group
Group type: COMPARATOR
Intervention: No plan
Number of subjects: 0
Study 14572191 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 40
Study 14572191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10392325 — intervention group
Group type: COMPARATOR
Intervention: Bosentan 100 mg
Number of subjects: 0
Study 10392325 — intervention group
Group type: COMPARATOR
Intervention: Bosentan 200 mg
Number of subjects: 0
Study 10392325 — intervention group
Group type: COMPARATOR
Intervention: Bosentan 500 mg
Number of subjects: 0
Study 10392325 — intervention group
Group type: COMPARATOR
Intervention: Bosentan 1000 mg
Number of subjects: 0
Study 10392325 — intervention group
Group type: COMPARATOR
Intervention: Bosentan 500 mg (with additional IV doses)
Number of subjects: 0
Study 10392325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10392325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (all doses)
Number of subjects: 0
Study 10392325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (doses above 500 mg)
Number of subjects: 0
Study 10392325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (oral treatment phase)
Number of subjects: 0
Study 10392325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study 8922245 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-containing single, alternating or 'hybrid' combination chemotherapy regimens
Number of subjects: 0
Study 8922245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality regimens with chemotherapy and radiation therapy
Number of subjects: 0
Study 8922245 — intervention group
Group type: COMPARATOR
Intervention: Single regimens of the MOPP type
Number of subjects: 0
Study 8922245 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 1858176 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 63
Study 1858176 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg indometacin
Number of subjects: 63
Study 1858176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 1858176 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment with 250 mg naproxen b.i.d.
Number of subjects: 63
Study 1858176 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 63
Study 29551226 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of quadrivalent HPV vaccine (Gardasil™)
Number of subjects: 17729
Study 29551226 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent HPV vaccine (Gardasil™)
Number of subjects: 17729
Study 29551226 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of quadrivalent HPV vaccine (Gardasil™)
Number of subjects: 17729
Study 29551226 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control women
Number of subjects: 17729
Study 26728036 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded screws with NiTi coil
Number of subjects: 51